Healthcare Research Reports

                 SHRNA https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html RNA Interference (RNAi) was first discovered in the 1980s and the concept won a Nobel prize in the year 2006. USFDA and EMA approved the first RNAi therapeutic , ONPATTRO® (developed by Alnylam Pharmaceuticals) in August 2018 which resulted in a rise in investor’s interest in the field. Most of the RNAi therapeutics have been discovered and several developers are engaged in the domain to discover the improvement in the existing platforms. The 380-pages report “RNAi Therapeutics Market (2nd Edition), 2019-2030: Focus On siRNA, miRNA, shRNA and DNA” features the current marketing scenario and trends in the evolving market. Also, the report presents the pipeline of participants engaged in the development phase.

Cell Therapy The approval of more than hundred drugs by USFDA in last five years for the treatment of various types of cancer with the help of Car-T Therapies has motivated cell-therapy products manufacturing companies to conduct clinical trials and develop novel therapy. As per reports of International Agency for Research on Cancer (IARC), in the year 2018 around 17 million new cases of cancer were diagnosed and it is estimated to rise 70% by 2040 to 27.5 million. The 983-pages report “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030” highlights the potential and rising demand for cell therapy treatment to eradicate tumour cells.

Bipolar Disorder Depression is a chronic disease where a patient goes through a consistent feeling of sadness and lack of interest. It is one of the leading cause of disability globally and it is estimated that approximately 300 million people have suffered from depression worldwide. Several drugs have been approved to treat depression. The 242-pages report “Depressive Disorders Market: Pipeline Review, Developer Landscape and Competitive Insights” highlights the types of (major depressive disorder such as bipolar disorder , postpartum depression, treatment-resistant depression and major depression. The report also covers up the major leaders in this domain. https://www.rootsanalysis.com/reports/view_document/depressive-disorders-major-depression-bipolar-disorder-postpartum-depression-treatment-resistant-depression-and-others-pipeline-review-developer-landscape-and-competitive-insights-2019/252.html

Companion Diagnostics Companies The healthcare industry witnessed a shift in medication with the introduction of personalized treatment option. As per the reports, around 50% prescribed drugs failed and also resulted in death due to side effects. To eliminate the obstacle in treatment, researchers came up with personalized therapies and genetic signatures. To take personalized therapy forward a physician requires patients’ companion diagnostics which can be ascertained with unique genetic profiles. The 300 – pages report “Companion Diagnostics Market (2nd Edition), 2019-2030” highlights the future potential of companion diagnostics and current companion diagnostic companies .

Bone Cement Delivery System A study conducted by the International Osteoporosis Foundation (IOF) states that around 200 million individuals suffer from Osteoporosis. It is a disease most prevalent among elders which weakens the bone density and enhances the risk of osteoporotic fracture. The latest data shows that an osteoporotic injury occurs in every three seconds. It is also estimated that global elder population will increase to 1.3 billion by 2030. To avoid the socioeconomic burden, the researchers are working on bone cement delivery systems to conduct different types of orthopaedic surgeries with the help of orthopedic bone cement. The 522-pages report “ Bone Cement Delivery Systems Market, 2019-2030” highlights the published patents and stakeholders involved in this domain.

Embryonic Stem Cells With rapid progress in the field of cell biology, several stem cell therapies have been developed by a list of stem cell companies. The promising pipeline anticipates the estimated revenue for the stem cell company to USD 100 Billion by 2030. The stem cell manufacturing requires a state of the art technologies which demands huge investments. Because of this, many cell therapy developers outsource and opt for stem cell contract. The 380-pages report “Stem Cell Therapies Contract Manufacturing Market, 2019 – 2030” features the list of stem cell companies involved in manufacturing of embryonic stem cells . The report also highlights the capabilities of contract manufacturing stem cell company. https://www.rootsanalysis.com/reports/view_document/stem-cell-therapy-contract-manufacturing-market-2019-2030/271.html